EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a serum-based microRNA panel for Alzheimer's disease diagnosis

Qi Qin, Xinyi Xia, Xinyu Zhang, Songtao Yang, Guodong Zhao, Chang Su iD, Yi Tang iD

Journal of Translational Internal Medicine · 25.06.2026 · 14 (3) · 456-469

DOI: 10.1515/jtim-2026-0038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Translational Internal Medicine, online erschienen am 13.06.2026. Verfasst von Qi Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives MicroRNAs (miRNAs) are emerging as promising blood-based biomarkers for Alzheimer's disease (AD) because of their stability and regulatory roles in disease-related pathways. This study aimed to develop a serum-based miRNA panel for AD diagnosis.

Methods

Serum samples from 550 participants were categorized into discovery (85 AD, 65 healthy controls [HCs]), training (73 AD, 53 HCs), and validation (99 AD, 99 HCs, 36 vascular cognitive impairment [VCI], 40 dementia with Lewy bodies [DLB]) cohorts. Through small RNA sequencing and qPCR validation, we identified key miRNAs and constructed a diagnostic panel via machine learning.

Results

The 7-miRNA panel achieved area under the curve (AUC) values of 0.970 and 0.928 in the training and validation cohorts, respectively. The panel effectively differentiated AD from VCI (AUC = 0.951) and DLB (AUC = 0.851). Diagnostic performance remained robust across subgroups defined by age, gender, disease severity, and comorbidities (AUC 0.758–0.988). The risk score derived from the 7-miRNA panel was significantly associated with cognitive impairment (Mini-Mental State Examination [MMSE] score, r = -0.72) and plasma amyloid pathology biomarkers (Aβ42/40 ratio, r = -0.25; p-tau217, r = 0.36).

Conclusions

A serum-based 7-miRNA panel, which offers a minimally invasive and accessible approach, has strong diagnostic potential for AD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkerdiagnosismicroRNAsserum

Autor:innen und Institutionen

  • Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China.
  • Miracle (Shenzhen) Biotechnology Co., Ltd., Shenzhen, Guangdong Province, China.
  • School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Neurodegenerative Laboratory of Ministry of Education of the People's Republic of China, Beijing, China.

ORCID-Profile: Chang Su, Yi Tang

Zitieren

APA

Qin, Q., Xia, X., Zhang, X., Yang, S., Zhao, G., Su, C., & Tang, Y. (2026). Development of a serum-based microRNA panel for Alzheimer's disease diagnosis. Journal of Translational Internal Medicine, 14(3), 456-469. https://doi.org/10.1515/jtim-2026-0038

Vancouver

Qin Q, Xia X, Zhang X, Yang S, Zhao G, Su C, et al. Development of a serum-based microRNA panel for Alzheimer's disease diagnosis. Journal of Translational Internal Medicine. 2026;14(3):456-469. doi:10.1515/jtim-2026-0038

BibTeX
@article{Qin2026,
  author = {Qin, Qi and Xia, Xinyi and Zhang, Xinyu and Yang, Songtao and Zhao, Guodong and Su, Chang and Tang, Yi},
  title = {Development of a serum-based microRNA panel for Alzheimer's disease diagnosis},
  journal = {Journal of Translational Internal Medicine},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {456--469},
  doi = {10.1515/jtim-2026-0038}
}
Kostenlos starten →